Fukang Pharm

Shouguang Fukang Pharmaceutical Co, Ltd. specializes in the development, manufacturing and marketing of 5 core product categories. They are PHARMACEUTCAL API, INTERMEDITES and FINISHED DOSE as well as BROMIDE COMPOUNDS and PAPER ADDITIVES, with a total of more than 60 products. Our production and sales volume of the API, trimethoprim (TMP), accounts for more than 70% of the world market. We are the No. 1 domestic producer and marketer of omeprazole, sulfamethoxazole (SMZ) and metformin HCl and the largest production base of bromide compounds. In a joint venture with BASF, we produce the following paper additives; ODB-II, ODB-I, S-205 and EGTE, to the highest international standards. Shouguang Fukang has established and implemented comprehensive quality assurance and quality control systems, with certifications of ISO9001/14001 and OHSAS18001. Shouguang Fukang was one of the first companies to receive SFDA GMP certification and five of our APIs, TMP, SMZ, omeprazole, metformin HCl and clozapine, have successfully passed USFDA inspection in Year 2011. We also gained COS certification from the European Directorate for the Quality of Medicines (EDQM). In addition we have successfully passed quality site audits from numerous renowned multinational corporations. Our company's products are domestically sold in 26 provinces and are exported to over 60 countries worldwide. Shouguang Fukang has been focusing its effort in research and development. It was certified as one of the Shandong Provincial Enterprise Technology Centers with distinguished oversea experts in house. Shouguang Fukang is named one of the Shandong Provincial Enterprise Technology Centers for its Bromine research and technological and engineering advances with three awards for The Advancement of Shangdong Science and Technology and two awards for Significant Innovation and Technology Transfer. On the national level, Shouguang Fukang has been awarded with grants for the following projects: four Projects for